Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin crossover study of microvascular and macrovascular circulation in type 2 diabetes
2013-004169-14Phase 3Completed
- Sponsor
- University Hospital Erlangen
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University Hospital Erlangen. Primary endpoint: Retinal capillary flow. Started Dec 2013; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-004169-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004169-14.